Results 91 to 100 of about 27,758 (263)

MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors [PDF]

, 2009
Increased activity of MYC protein-family members is a common feature in many cancers. Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor ...
Speleman, Franki, F Westermann, De Preter, Katleen, Vermeulen, Joëlle, Laureys, Genevieve, Schulte, JH, Pattyn, Filip, F Speleman, Schlierf, S, Kumps, Candy, G Laureys, R Noguera, P Mestdagh, Schramm, A, Vandesompele, Jo, J H Schulte, A Schramm, Eggert, A, D Muth, F Pattyn, Mestdagh, Pieter, Muth, D, Van Roy, Nadine, J Vermeulen, A Eggert, J Vandesompele, Fredlund, E, Noguera, R, S Schlierf, Westermann, F, N Van Roy, E Fredlund, K De Preter, C Kumps   +33 more
core   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

Metastasis in neuroblastoma: the MYCN question

Frontiers in Oncology, 2023
Oncogenic drivers like MYCN in neuroblastoma subsets continues to present a significant challenge owing to its strong correlation with high-risk metastatic disease and poor prognosis. However, only a limited number of MYCN-regulatory proteins associated with tumor initiation and progression have been elucidated.
openaire   +4 more sources

A Living Multi‐Omics PDX Biobank of High‐Risk Sarcomas Reveals ecDNA‐Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology

Advanced Science, EarlyView.
A living multi‐omics sarcoma PDX biobank is enriched for high‐risk disease and preserves key patient tumor features at histopathological and molecular levels. Integrated profiling reveals ecDNA‐driven oncogene amplification in osteosarcoma and preferential retention of ecDNA during PDX evolution.
Weisong Zhao, Zhiwei Cheng, Kai Tian, Mengxiong Sun, Zhuoying Wang, Ming Jiao, Jens Luebeck, Kaiyuan Zhu, Xiao Zhang, Dongqing Zuo, Hongsheng Wang, Chongren Wang, Jiakang Shen, Xiaojun Ma, Gangyang Wang, Zongyi Wang, Jing Han, Kaiyuan Liu, Haoran Mu, Weiqi Ma, Yongyong Ren, Shibing Guo, Huangxin Tu, Lingfeng Yu, Yining Tao, Yu Lv, Hui Lu, Owen S. Chapman, Rishaan Kenkre, Lukas Chavez, Zhengdong Cai, Yuqin Yang, Wei Sun, Yafei Jiang, Yingqi Hua   +34 more
wiley   +1 more source

Function of Oncogene Mycn in Adult Neurogenesis and Oligodendrogenesis [PDF]

, 2021
Human MYCN is an oncogene amplified in neuroblastoma and many other tumors. Both human MYCN and mouse Mycn genes are important in embryonic brain development, but their functions in adult healthy nerve system are completely unknown.
Guan, Zhonghui, Chen, Jiao, Zhonghui Guan, Jiao Chen   +3 more
core   +1 more source

Heterogeneity of the MYCN Oncogene in Neuroblastoma [PDF]

Clinical Cancer Research, 2009
Abstract Purpose: MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity.
Theissen, J, Boensch, M, Spitz, R, Betts, D, Stegmaier, S, Christiansen, H, Niggli, F, Schilling, F, Schwab, M, Simon, T, Westermann, F, Berthold, F, Hero, B   +12 more
openaire   +2 more sources

MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma

Cell Death and Disease
MYCN amplification is an independent poor prognostic factor in patients with high-risk neuroblastoma (NB). Further exploring the molecular regulatory mechanisms in MYCN-amplified NB will help to develop novel therapy targets.
J. Guan, Meng-Zhen Li, Yi Wang, Yu Zhang, Y. Que, Su-Ying Lu, Juan Wang, Jia Zhu, Jun-Ting Huang, Zi-Jun Zhen, Fei-Fei Sun, Meng-Jia Song, Yi-Zhuo Zhang   +12 more
semanticscholar   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer

Frontiers in Oncology, 2015
The MYCN proto-oncogene is associated with poor outcome across a broad range of pediatric tumors. While amplification of MYCN drives subsets of high risk neuroblastoma and medulloblastoma, dysregulation of MYCN in medulloblastoma (in the absence of ...
Tene Aneka Cage, Yvan eChanthery, Yvan eChanthery, Louis eChesler, Matthew eGrimmer, Matthew eGrimmer, Zachary eKnight, Kevan eShokat, William A Weiss, William A Weiss, William A Weiss, William A Weiss, W. Clay Gustafson, W. Clay Gustafson   +13 more
doaj   +1 more source

p53 is a direct transcriptional target of MYCN in neuroblastoma.

, 2010
MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis.
PERINI, GIOVANNI, Lunec J., Tweddle D. A., Iraci N., Gamble L. D., GHERARDI, SAMUELE, Chen L., Wood K. M., Wood KM, Chen LD, Tweddle DA, IRACI, NUNZIO, Gherardi S, Lunec J, Perini G, Gamble LD   +15 more
core   +1 more source